|
1
|
Sehgal V and Srivastava G: Vitiligo:
compendium of clinico-epidemiological features. Indian J Dermatol
Venereol Leprol. 73:149–156. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Guerra L, Dellambra E, Brescia S and
Raskovic D: Vitiligo: pathogenetic hypotheses and targets for
current therapies. Curr Drug Metab. 11:451–467. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Steiner D, Bedin V, Brito M, Tadeu R and
Steiner T: Vitiligo. An Bras Dermatol. 79:335–351. 2004. View Article : Google Scholar
|
|
4
|
Parsad D, Dogra S and Kanwar AJ: Quality
of life in patients with vitiligo. Health Qual Life Outcomes.
1:58–63. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Moretti S: Vitiligo: Orphanet
Encyclopedia. October. 2003, http://www.orpha.net/data/patho/GB/uk-vitiligo.pdfuri.
Accessed December 13, 2013
|
|
6
|
Huggins RH, Janusz CA and Schwartz RA:
Vitiligo: a sign of systemic disease. Indian J Dermatol Venereol
Leprol. 72:68–71. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jin Y, Mailloux CM, Gowan K, et al: NALP1
in vitiligo-associated multiple autoimmune disease. N Engl J Med.
356:1216–1225. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
van Gell N, Speeckaert M, et al: Clinical
profile of generalized vitiligo patients with associated
autoimmune/autoinflammatory diseases. J Eur Acad Dermatol Venereol.
28:741–746. 2014.PubMed/NCBI
|
|
9
|
Shajil EM, Chatterjee S, et al: Vitiligo:
pathomechanisms and genetic polymorphism of susceptible genes.
Indian J Exp Biol. 44:526–539. 2006.PubMed/NCBI
|
|
10
|
Kemp EH, Gavalast NG, et al: Autoantibody
responses to melanocytes in the depigmenting skin disease vitiligo.
Autoimmun Rev. 6:138–142. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Almeida P, Borrego L, Rodríguez-López J,
et al: Vitiligo. Treatment of 12 cases with topical tacrolimus.
Actas Dermosifiliogr. 96:159–163. 2005.(In Spanish).
|
|
12
|
Xu AE, Zhang DM, Wei XD, Huang B and Lu
LJ: Efficacy and safety of tarcrolimus cream 0.1% in the treatment
of vitiligo. Int J Dermatol. 48:86–90. 2009.PubMed/NCBI
|
|
13
|
Amur S, Parekh A and Mummaneni P: Sex
differences and genomics in autoimmune diseases. J Autoimmun.
38:J254–J165. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cohen S, Dadi H, Shaoul E, Sharfe N and
Roifman CM: Cloning and characterization of a lymphoid-specific,
inducible human protein tyrosine phosphatase, Lyp. Blood.
93:2013–2024. 1999.PubMed/NCBI
|
|
15
|
Zhebrun D, Kudryashova Y, Babenko A, et
al: Association of PTPN22 1858T/T genotype with type 1 diabetes,
Graves’ disease but not with rheumatoid arthritis in Russian
population. Aging (Albany NY). 3:368–373. 2011.PubMed/NCBI
|
|
16
|
Torres-Carrillo NM, Ruiz-Noa Y, et al: The
+1858C/T PTPN22 gene polymorphism confers genetic susceptibility to
rheumatoid arthritis in Mexican population from the Western Mexico.
Immunol Lett. 147:41–46. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cénit MC, Márquez A, Cordero-Coma M, et
al: Lack of association between the protein tyrosine phosphatase
non-receptor type 22 R263Q and R620W functional genetic variants
and endogenous non-anterior uveitis. Mol Vis. 19:638–643.
2013.PubMed/NCBI
|
|
18
|
Chen YF and Chang JS: PTPN22 C1858T and
the risk of psoriasis: a meta-analysis. Mol Biol Rep. 39:7861–7870.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bottini N, Musumeci L, Alonso A, et al: A
functional variant of lymphoid tyrosine phosphatase is associated
with type I diabetes. Nat Genet. 36:337–338. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cantón I, Akhtar S, Gavalas NG, Gawkrodger
DJ, Blomhoff A, Watson PF, Weetman AP and Kemp EH: A
single-nucleotide polymorphism in the gene encoding lymphoid
protein tyrosine phosphatase (PTPN22) confers susceptibility to
generalised vitiligo. Genes Immun. 6:584–587. 2005.PubMed/NCBI
|
|
21
|
Vang T, Miletic AV, Bottini N and Mustelin
T: Protein tyrosine phosphatase PTPN22 in human autoimmunity.
Autoimmunity. 40:453–461. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zikherman J, Hermiston M, Steiner D,
Hasegawa K, Chan A and Weiss A: PTPN22 deficiency cooperates with
the CD45 E613R allele to break tolerance on a nonautoimmune
background. J Immunol. 182:4093–4106. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Laberge GS, Birlea SA, Fain PR and Spritz
RA: The PTPN22-1858C>T (R620W) functional polymorphism is
associated with generalized vitiligo in the Romanian population.
Pigment Cell Melanoma Res. 21:206–208. 2008.
|
|
24
|
Baca V, Velázquez-Cruz R, Salas-Martínez
G, Espinosa-Rosales F, Saldaña-Alvarez Y and Orozco L: Association
analysis of the PTPN22 gene in childhood-onset systemic lupus
erythematosus in Mexican population. Genes Immun. 7:693–695. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Harrison P, Pointon JJ, Farrar C, Brown MA
and Wordsworth BP: Effects of PTPN22 C1858T polymorphism on
susceptibility and clinical characteristics of British Caucasian
rheumatoid arthritis patients. Rheumatology (Oxford). 45:1009–1011.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Aris M: Origin of normal and malignant
melanocytes. Acta Bioquím Clín Latinoam. 43:333–337. 2009.
|
|
27
|
Zhang XJ, Chen JJ and Liu JB: The genetic
concept of vitiligo. J Dermatol Sci. 39:137–146. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sandoval-Cruz M, García-Carrasco M,
Sánchez-Porras R, Mendoza-Pinto C, Jiménez-Hernández M,
Munguía-Realpozo P and Ruiz-Argüelles A: Immunopathogenesis of
vitiligo. Autoimmun Rev. 10:762–765. 2011. View Article : Google Scholar
|
|
29
|
Sahni K and Parsad D: Stability in
vitiligo: Is there a perfect way to predict it? J Cutan Aesthet
Surg. 6:75–82. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Spritz RA: The genetics of generalized
vitiligo and associated autoimmune diseases. Pigment Cell Res.
20:271–278. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Burn GL, Svensson L, Sanchez-Blanco C,
Saini M and Cope AP: Why is PTPN22 a good candidate susceptibility
gene for autoimmune disease? FEBS Lett. 585:3689–3698. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang J, Zahir N, Jiang Q, Miliotis H,
Heyraud S, Meng X, Dong B, Xie G, Qiu F, Hao Z, McCulloch CA,
Keystone EC, Peterson AC and Siminovitch KA: The autoimmune
disease-associated PTPN22 variant promotes calpain-mediated Lyp/Pep
degradation associated with lymphocyte and dendritic cell
hyperresponsiveness. Nat Genet. 43:902–907. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang CQ, Cruz-Inigo AE, Fuentes-Duculan J,
Moussai D, Gulati N, Sullivan-Whalen M, Gilleaudeau P, Cohen JA and
Krueger JG: Th17 cells and activated dendritic cells are increased
in vitiligo lesions. PLoS One. 6:e189072011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lins TC, Vieira RG, Grattapaglia D and
Pereira RW: Allele and haplotype frequency distribution in PTPN22
gene across variable ethnic groups: Implications for genetic
association studies for autoimmune diseases. Autoimmunity.
43:308–316. 2010. View Article : Google Scholar
|
|
35
|
Elmongy NN and Abu Khalil RE: PTPN22 gene
polymorphism in Egyptian females with non-segmental vitiligo. Comp
Clin Pathol. 22:961–964. 2013. View Article : Google Scholar
|
|
36
|
Song GG, Kim JH and Lee YH: The CTLA-4 +49
A/G, CT60 A/G and PTPN22 1858 C/T polymorphisms and susceptibility
to vitiligo: a meta-analysis. Mol Biol Rep. 40:2985–2993. 2013.
View Article : Google Scholar : PubMed/NCBI
|
